We serve Chemical Name:(6-tert-butylpyridin-3-yl)boronic acid CAS:1174312-53-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(6-tert-butylpyridin-3-yl)boronic acid
CAS.NO:1174312-53-8
Synonyms:2-tert-butyl-pyridine-5-boronic acid
Molecular Formula:C9H14BNO2
Molecular Weight:179.02400
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:53.35000
Exact Mass:179.11200
LogP:0.05890
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-tert-butyl-pyridine-5-boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-tert-butyl-pyridine-5-boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-tert-butyl-pyridine-5-boronic acid Use and application,2-tert-butyl-pyridine-5-boronic acid technical grade,usp/ep/jp grade.
Related News: The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. 2-(2-(4-(2-(benzylamino)-1-cyclopentyl-2-oxoethyl)phenoxy)acetyl)benzoic acid manufacturers It has also been possible to prepare enzymes that can function effectively in organic solvents, thereby dramatically increasing the number of reactions possible. Clarifiedoils (shale oil), hydrocracked, catalytic cracked suppliers It has also been possible to prepare enzymes that can function effectively in organic solvents, thereby dramatically increasing the number of reactions possible. 1-(5-(bis(2-hydroxyethyl)amino)-2-(2-chlorophenyl)-2a,3,4,5-tetrahydrobenzo[cd]indol-1(2H)-yl)ethan-1-one vendor & factory The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment.,As for the consumer health unit, GSK plans to demerge it by mid-2022, during which GSK will shed at least 80% of its 68% holding in the JV to shareholders.
